Bioavailability of Different Formulations of Metformin Hydrochloride in Healthy Volunteers: a Comparative Study
Objective: To assess the bioavailability of a formulation of metformin hydrochloride 850 mg coated tablets as test, compared to a reference product with the same dosage form, in healthy volunteers of both genders. Method: This clinical trial was designed as randomised, comparative, single-dose, open-label, two-period, two-sequence, crossover study under fasting conditions. 28 healthy volunteers (fourteen men and fourteen women) took part in the study. The 850 mg coated tablets formulations were administered in a single dose orally. Blood samples were obtained prior to dosing and at 30 min, 1, 1:20; 1:40, 2, 2:20, 2:40; 3, 3:20, 3:40 4, 4:30, 5, 6, 8, 12, 16, 24 and 36 hours after drug administration with an one week washout period. Plasmatic concentrations of metformin were measured by specific and validated analytical methods based on high-performance liquid chromatography coupled to mass spectrometry (HPLC/MS). The pharmacokinetics parameter AUC0-36h, AUC0-∞ and Cmax were tested for bioequivalence after log transformation of data and ratios of Tmax were evaluated non parametrically. Findings: Data from this study showed that the test and the reference formulation presented similar results, within the acceptance range (80-125%) for AUC0-∞ (area under curve) and Cmax (maximum serum concentration of the drug) parameters, satisfying the bioequivalence criteria of the Brazilian Health Surveillance Agency and FDA. Conclusion: These results indicate that the two formulations of metformin hydrochloride 850 mg coated tablets are bioequivalent, thus, it will be possible to ensure interchangeability between them, which can generate market competition and better access to this treatment.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).